Antitope and Baylor Institute for Immunology Research to Collaborate on Cell Line for Novel Therapeutic Dendritic-cell-targeting Vaccine
Antitope has developed the Composite CHO™ technology for the generation of stable cell lines producing high yields of proteins and antibodies ready for cGMP manufacture. The current project represents another milestone in the relationship between Antitope and BIIR, initiated several years ago when Antitope applied its Composite Human Antibody™ technology to humanize several novel BIIR antibodies. The humanized antibodies have been an important tool for BIIR in the development of its therapeutic vaccines.
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.